X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of “Moderate Buy” from Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $11.25.

Several equities research analysts have recently issued reports on the stock. Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Wells Fargo & Company assumed coverage on shares of X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective on the stock. Finally, Leerink Partners began coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price objective for the company.

X4 Pharmaceuticals Stock Down 2.1%

X4 Pharmaceuticals stock opened at $4.21 on Wednesday. X4 Pharmaceuticals has a 12 month low of $2.45 and a 12 month high of $4.83. The stock has a fifty day simple moving average of $4.07 and a two-hundred day simple moving average of $3.97. The firm has a market cap of $417.42 million, a price-to-earnings ratio of -3.51 and a beta of 0.37. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. The company had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. Equities analysts predict that X4 Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Insider Transactions at X4 Pharmaceuticals

In related news, President John Volpone sold 24,576 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $109,117.44. Following the completion of the sale, the president directly owned 265,305 shares of the company’s stock, valued at approximately $1,177,954.20. This trade represents a 8.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Kirske sold 8,543 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total value of $36,393.18. Following the transaction, the chief financial officer owned 167,750 shares of the company’s stock, valued at approximately $714,615. The trade was a 4.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 80,555 shares of company stock worth $356,126. 1.13% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Pettinga Financial Advisors LLC purchased a new position in X4 Pharmaceuticals in the 2nd quarter worth about $47,000. Indivisible Partners bought a new stake in X4 Pharmaceuticals during the 4th quarter valued at about $40,000. SummitTX Capital L.P. purchased a new stake in X4 Pharmaceuticals in the 1st quarter valued at about $46,000. Squarepoint Ops LLC purchased a new stake in X4 Pharmaceuticals in the 4th quarter valued at about $50,000. Finally, Two Sigma Investments LP bought a new position in X4 Pharmaceuticals in the 3rd quarter worth about $47,000. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.